BMY-14802

BMY-14802

BMY-14802
Systematic (IUPAC) name
1-(4-fluorophenyl)-4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]butan-1-ol
Clinical data
Legal status
?
Identifiers
CAS number  YesY
ATC code None
PubChem
ChemSpider  N
ChEMBL  N
Chemical data
Formula C18H22F2N4O 
Mol. mass 348.389 g/mol
 N   

BMY-14802 is a drug with antipsychotic effects, which acts as both a sigma receptor antagonist, and a 5-HT1A agonist.[1][2][3][4]

References

  1. ^ Taylor DP, Eison MS, Moon SL, Schlemmer RF, Shukla UA, VanderMaelen CP, Yocca FD, Gallant DJ, Behling SH, Boissard CG (1993). "A role for sigma binding in the antipsychotic profile of BMY 14802?". NIDA Research Monograph 133: 125–57.  
  2. ^ Vanecek SA, Essman WD, Taylor DP, Woods JH (January 1998). "Discriminative stimulus characteristics of BMY 14802 in the pigeon". The Journal of Pharmacology and Experimental Therapeutics 284 (1): 1–9.  
  3. ^ Kitanaka J, Kitanaka N, Tatsuta T, Hall FS, Uhl GR, Tanaka K, Nishiyama N, Morita Y, Takemura M (May 2009). "Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice". Psychopharmacology 203 (4): 781–92.  
  4. ^ Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP (July 2009). "The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism". Psychopharmacology 204 (4): 743–54.